Allergy Therapeutics AAQS 2025

Ką veikia Allergy Therapeutics?

Allergy Therapeutics PLC is a British biotechnology company specializing in researching, developing, and marketing vaccines and therapeutics for the treatment of allergic diseases. The company was founded in 1999 and is headquartered in Worthing, West Sussex. It is listed on the London Stock Exchange and has branches in Europe and the USA. Business model: Allergy Therapeutics' business model is based on researching allergic diseases to develop immunotherapeutics that can alleviate or eliminate allergy symptoms by activating the immune system. The products primarily include sublingual tablets (SLIT) and injectable allergen extracts (AIT). The company generates revenue through the sale of medications and licensing agreements with partners in Europe and other regions. Divisions and products: Allergy Therapeutics specializes in the treatment of allergies such as hay fever, asthma, and allergic rhinitis. The company has four divisions - Europe, USA, International, and New Developments - which focus on specific areas. Europe is Allergy Therapeutics' main division and currently includes the British, French, Italian, Spanish, German, and Dutch markets. In Europe, the company has three main products: Pollinex Quattro, Pollinex, and Venomil. Pollinex Quattro is a vaccine commonly used for allergen-specific immunotherapy to immunize the body against allergens such as pollen, dust mites, or mold spores. Pollinex is a sublingual vaccine taken in the form of drops or tablets. Venomil is a vaccine specifically developed for the treatment of insect venom allergies. The USA division consists of AllerVac, Allergy Therapeutics' product range in the USA, specializing in the production and marketing of injectable allergen extracts. AllerVac is used as a first-line therapy for allergic diseases in the USA and is an important approach for treating asthma and rhinitis. The International division aims to distribute Allergy Therapeutics products worldwide. The products are available in various regions, including Australia, Scandinavia, China, India, and South Africa. The New Developments division focuses on researching and developing new vaccine and therapy products for the treatment of allergic diseases, including the product Synexus. Overall, Allergy Therapeutics has an extensive portfolio of products that help alleviate the symptoms of allergic diseases and improve the quality of life for those affected. Conclusion: Allergy Therapeutics PLC is a biotechnology company specializing in researching, developing, and marketing immunotherapeutics for the treatment of allergic diseases. The company's products reduce symptoms of allergies such as hay fever, asthma, and allergic rhinitis. Allergy Therapeutics has four divisions - Europe, USA, International, and New Developments - and a wide portfolio of products available in various regions of the world. Allergy Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.